Home > Ana Maria Arance Fernandez, ESMO 2020 – Lenvatinib plus Pembrolizumab for Advanced Melanoma: Initial Results of LEAP-004
Dermatological Cancer

Ana Maria Arance Fernandez, ESMO 2020 – Lenvatinib plus Pembrolizumab for Advanced Melanoma: Initial Results of LEAP-004

Published Online: October 1st 2020
Authors: Ana Maria Arance Fernandez,

touchONCOLOGY meets with Dr Ana Maria Arance Fernandez at ESMO 2020 to discuss findings from the LEAP-004 trial, and the role lenvatinib plus pembrolizumab can play in the treatment of advanced melanoma. The late-breaking abstract ‘Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004’ (LBA44) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020. 

Questions

  1. What is the rationale for the combined use of lenvatinib plus pembrolizumab in the treatment of advanced melanoma that has progressed on PD-1/PD-L1 inhibitor therapy? (0:11)
  2. Could you tell us a little about the aims and design of the LEAP-004 study? (0:38)
  3. What were the main efficacy and safety findings of the study? (1:33)
  4. What association (if any) was found between treatment response and PD-L1 status? (2:31)
  5. What are the remaining gaps in our knowledge and what future studies are planned? (3:01)

Speaker Disclosure: Ana Maria Arance Fernandez has nothing to disclose in relation to this interview. 

Support: Interview and filming supported by Touch Medical Media Ltd. The LEAP-004 trial was sponspored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. 

Filmed in coverage of the Virtual 2020 ESMO Congress.

PD-1 = Programmed cell death protein 1; PD-L1 = Programmed death-ligand 1.

Share this Video
Related Videos In Dermatological Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar